Identifying novel therapeutic targets based on cancer vulnerabilities remains a promising strategy to effectively delay disease progression and improve outcome of ERα-positive breast cancer patients regardless of the presence of ESR1 mutations. The gene discussed is ESR1; the disease is breast cancer.